evidence card · orforglipron_phase3_efficacy
Orforglipron (oral GLP-1) produces ~16% body-weight loss in Phase 3 and beats oral semaglutide head-to-head
H5
▲ supports
stakes high
0 posts scored
·
across 0 accounts
·
1 sources
Summary
Phase 3 trials reported in The Lancet (2026) show ~16% weight loss and superiority vs oral semaglutide. Long-term cardiovascular outcome data not yet available.
Five-score assessment
Scores not yet assigned for this card. (Legacy card; will be populated on next refinement.)
Scope
Population
adults with obesity (Phase 3 population)
Intervention
orforglipron daily oral
Outcome
body weight, glycemia
Not supported for
- long-term safety beyond trial duration; direct CV events
Evidence sources
Account mentions
No accounts have made claims mapped to this card yet.